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Abstract Protein therapeutics have emerged as a major new
class of pharmaceuticals. One important shelf-life-limiting
factor of biopharmaceuticals is methionine oxidation, and
therefore, it is important that analytical methods are able to
thoroughly characterize all possible oxidized variants. Here,
we present a fast and sensitive method to perform online
methionine oxidation site assignment using granulocyte
colony-stimulating factor (filgrastim) as a model. The meth-
od is based on top-down MS using the all-ion fragmentation
mode of the Exactive benchtop mass spectrometer.
Conditions that provide information on the intact mass of
the protein as well as on fragment ions that allow un-
ambiguous site assignment of methionine oxidation in
filgrastim variants as low as 0.12 % of total peak area
in a chromatographic time scale were identified. Using
this method, we performed methionine oxidation site
assignment in H2O2-stressed filgrastim and in filgrastim
which was stored at intended conditions, respectively. We
show that the relative abundance of oxidation species
observed in filgrastim stored under intended conditions
differs strikingly from the oxidized species observed after
H2O2 stress. Additionally, we report an oxidized
filgrastim variant that has not been previously described
in the literature.
Keywords G-CSF .Filgrastim .Mass spectrometry .All-ion
fragmentation . Top-downMS .Methionine oxidation . Site
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Introduction
Granulocyte colony-stimulating factor (G-CSF) is a hemato-
poietic growth factor and cytokine that stimulates the produc-
tion of neutrophils and affects neutrophil progenitor prolifera-
tion, differentiation, and cell functional activation [1, 2].
Recombinant human G-CSF (rhG-CSF; INN filgrastim)
expressed in Escherichia coli was one of the first biopharma-
ceuticals to be commercialized (Neupogen®; Amgen Inc.). It is
a 175-amino acid long non-glycosylated polypeptide with an
additional N-terminal methionine residue not found in the
native endogenous human protein. Filgrastim is largely used
to treat neutropenia as well as infectious complications, which
can be associated with chemotherapy [3, 4]. Following the
patent expiration of the reference product in the European
Union, three biosimilar filgrastims have been approved [5],
one of which is Zarzio® (Sandoz). Due to the introduction of
more affordable biosimilar versions of filgrastim, some coun-
tries have managed to move filgrastim back to prophylactic use
in order to reduce the incidence of febrile neutropenia after
chemotherapy, thereby preventing hospital readmission due to
infections [6–9]. Patient-friendly application devices together
with new formulations are crucial to further enhance patient
access. Their development, however, requires close monitoring
of filgrastim-related impurities that occur due to physical or
chemical degradation of the protein.
One important shelf-life-limiting degradation product of
filgrastim is the oxidation of methionine residues to their
sulfoxide derivatives. Filgrastim contains four methionine
residues (Met1, Met122, Met127, andMet138) and an extensive
body of literature is available on the analytical and biological
characterization of H2O2-induced oxidized variants [10–15].
Quantification of methionine oxidation in proteins is usually
performed by reverse-phase HPLC (RP-HPLC). Since each
of the four methionine residues in filgrastim is susceptible to
oxidation, it is important that analytical methods are able to
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thoroughly characterize all possible oxidized variants.
Assignment of the methionine oxidation site is routinely
performed by isolation of individual oxidized species and
subsequent enzymatic (e.g., GluC) or chemical (e.g., CNBr)
cleavage of the protein (bottom-up approach). The resulting
peptides are then subjected to liquid chromatography–mass
spectrometry (LC-MS) analysis (Fig. 1).
Site assignment of methionine oxidation using this
workflow has two major drawbacks: (1) a substantial amount
of sample is required to allow variant fractionation and
subsequent peptide mapping (especially for low abundant
variants) and (2) the procedure is time consuming, due to
elongated sample preparation and LC-MS analysis. Hence,
there exists a need for a fast and sensitive method for oxidation
site assignment in biopharmaceuticals such as filgrastim.
With the continuous improvement in instrumentation and
data analysis software, top-down MS is becoming a highly
attractive method for the characterization of proteins
[16–21]. The Orbitrap family of MS analyzers is a popular
and powerful tool for protein characterization due to its
capabilities of high resolution and high mass accuracy.
Top-down MS using this instrumentation has mostly been
reported for proteins with molecular weights <30 kDa, but
has also been successfully implemented for larger proteins
up to the size of intact antibodies (∼150 kDa), albeit with
lower resolution settings [22–27].
Herein, we report—for the first time—a top-down approach
on a benchtop Exactive mass spectrometer for online methio-
nine oxidation site assignment in a biopharmaceutical, using
the microbially produced drug filgrastim. The method provides
information on the intact mass of the protein variant as well as
on fragment ions that allow unambiguous site assignment of
methionine oxidation necessary for site-specific quantification
ofmethionine oxidation via UV.Using this top-down approach,
we also characterized an oxidized filgrastim variant that has not
been previously reported in the literature.
Materials and methods
Chemicals and study material
All chemicals purchased were of highest purity available.
Trifluoroacetic acid was obtained from Sigma-Aldrich
(Steinheim, Germany). HPLC grade water and acetonitrile
were purchased from J.T. Baker (Deventer, The Netherlands).
Forced oxidation using H2O2 was performed on Sandoz
filgrastim drug product (Zarzio®, formulation A) produced in
Fig. 1 The classic approach for
the assignment of methionine
oxidation involves isolation of
the individual oxidized species
and subsequent peptide
mapping using a specific
protease (e.g., GluC). (a)
Chromatographic separation of
oxidized filgrastim variants
following H2O2 treatment. (b)
Peptide mapping of Ox-2 and
Ox-3 fractions demonstrating
unique oxidation peak whose
site assignment could be
elucidated using MS and MS/
MS analysis (peaks labeled
according to theoretical digest,
e.g., G1 represents the first
peptide of a GluC digest; mass
spectrometry data are not
shown)
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house; the same batch of Zarzio® was used for selection of the
diagnostic fragment ions (Figs. 2, 3, and 4). For online Met
oxidation site assignment in samples stored under intended
conditions (Fig. 5), Sandoz filgrastim development samples
(formulation B) and Neupogen® were used. Neupogen® was
sourced from Amgen (Amgen Inc., Thousand Oaks, CA) and
stored under intended storage conditions.
Direct infusion of filgrastim and MS analysis
Sandoz filgrastim drug product (Zarzio®, formulation A) was
buffer exchanged into water using Microcon YM-3 centrifugal
filter devices (Millipore, Bedford, MA) and diluted with a
solution of 50 % acetonitrile (ACN) in 0.1 % trifluoroacetic
acid (TFA) to a final concentration of 1.1 mg/ml. A 500-μl
Hamilton syringe was used to infuse the sample directly into
the Exactive mass spectrometer at a flow rate of 10 μl/min. The
Exactive MS was operated in an all-ion fragmentation (AIF)
mode with the following settings applied: spray voltage 4 kV,
capillary temperature 275 °C, sheath gas 20, aux gas 8, scan
range 200–2,000 m/z, resolution ultra high, AGC target 1e6,
max inject time 100 ms, and microscans 10. Higher energy
collision dissociation (HCD) fragmentation energy was manu-
ally varied between 15 and 45 eV. For data evaluation, spectra
acquired within a time frame of approximately 10 s were
averaged and deconvoluted using the Xtract algorithm
implemented into Xaclibur 2.1 Software (Thermo Scientific,
Bremen, Germany). The following parameters were used for
deconvolution: S/N threshold 2, fit factor 44 %, remainder
25 %, and max charge 20. The assignment of deconvoluted
AIF spectra was done manually using GPMAW 9.02 software
(Lighthouse data, Odense, Denmark) to predict the masses of
the individual fragment ions.
HPLC separation and all-ion fragmentation on Exactive MS
Nine micrograms of Sandoz filgrastim development sample
(drug product, formulation B), Sandoz filgrastim drug product
(Zarzio®; formulation A), and Neupogen®, respectively, was
separated on a Zorbax 300SB-C18 column (4.6×150 mm,
3.5 μm particle size) with a gradient of solutions A (0.1 %
TFA in water) and B (0.1%TFA in ACN) at a flow rate of
1 ml/min: 25min from 25%B to 54%B followed by a 32-min
gradient from 54 % B to 73 % B. After UV and fluorescence
detection, the flow was split 1:5 and then electrosprayed into
the Exactive MS. The mass spectrometer was again operated in
the AIF mode with settings applied as discussed above, except
that the mass range was set to 300 to 2,200m/z. Deconvolution
and data interpretation were performed as described above.
Results
Selection of diagnostic fragment ions
Direct infusion experiments using desalted filgrastim were car-
ried out for the selection of diagnostic fragment ions and the
optimization of HCD settings. Figure 2 shows the sequence
Fig. 2 Sandoz filgrastim drug product (Zarzio®) is a biosimilar of
filgrastim (recombinant human granulocyte colony-stimulation factor
(rhG-CSF)) and has a molecular weight of 18.8 kDa. It contains four
Met residues at positions 1, 122, 127, and 138 (highlighted in yellow). (a)
Sequence coverage generated by HCD with 35 eV. (b) Deconvoluted
HCD spectra of Sandoz filgrastim drug product (Zarzio®). The fragment
ions y47, y50, y78, and b97 allow assignment of all four Met residues
(highlighted in red), which can be oxidized under stressed conditions
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coverage and representative HCD spectrum obtained using our
top-down analysis of Sandoz filgrastim drug product (Zarzio®),
a biosimilar filgrastim, stored under intended storage conditions.
Despite sequence coverage of only 25 %, all-ion fragmen-
tation in the C-trap of the Exactive instrument produced
fragment ions (highlighted in red in Fig. 2a) that allowed
Fig. 3 Sandoz filgrastim drug
product (Zarzio®), a biosimilar
filgrastim, was subjected to
oxidation with (a) 0.1 % and (b)
0.5 % final concentration of
H2O2, separated on a RP C18
column and electrosprayed into
an Exactive mass spectrometer.
Peak assignment was performed
by detection of diagnostic ions
following HCD fragmentation
at 35 eV. Peaks labeled in
brackets indicate missing
fragment ions due to low
abundance. The HCD spectra of
peaks labeled in red are shown
in Fig. 4. The site of Met
oxidation can be
unambiguously assigned in
peaks as low as 0.70 % of total
peak area (M138ox+M127ox)
Fig. 4 HCD spectra of low abundance oxidized filgrastim variants labeled in
red in Fig. 3. (a) The diagnostic fragment ions for M127ox+M138ox
(y47+16 Da and y50+32 Da) were unambiguously identified in the HCD
spectra despite representing only 0.7 % of the total peak area. (b) Due to the
low abundance of the triply oxidized variant, which represents 0.12 % of the
total peak area, the diagnostic fragment ion y78 is missing. However, the
combination of native mass (18,788.01+48.3) and diagnostic ions y47,
y50+16 Da, and b97+16 Da allows the sites of oxidation to be elucidated
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the discrimination of all four oxidized methionine residues
found in filgrastim with reasonable intensity (Fig. 2b).
Fragment ion y47 (theoretical mass of 5,073.71 Da) is the
most abundant ion found in the HCD spectrum and is diag-
nostic for Met138. Fragment ion y50 (theoretical mass of
5,332.81 Da) contains Met127 and Met138, which, after con-
sidering the mass of y47, is diagnostic for Met127. Similarly,
fragment ion y78 (theoretical mass of 8,488.35 Da) contains
three methionine residues, Met122, Met127, and Met138, but
becomes diagnostic for Met122 af0ter considering the masses
of y50 and y47. Finally, fragment ion b97 (theoretical mass
of 10,300.34 Da) is diagnostic for Met1. In addition to the
diagnostic ions, we also observed some unfragmented parent
ion which allowed the simultaneous measurement of the
intact mass of filgrastim (theoretical monoisotopic mass
[M+H]+ of 18,787.68 Da). The average mass deviation over
all measured fragment ions was 11 ppm. As an alternative
approach, we also tested in-source collision-induced disso-
ciation, but were not able to detect fragment ions that could
discriminate between methionines at positions 127 and 138
(data not shown). From Fig. 1b, it can be deduced that the
sensitivity of the HCD method is limited by the intensity of
Fig. 5 (a) UV chromatogram of Neupogen® (black trace; analysis
performed 25 weeks after end-of-shelf-life, red trace analysis
performed 9 weeks before end-of-shelf-life, stored at 5±3 °C) and
filgrastim Sandoz development samples (green and blue traces, stored
for 34 weeks at 5±3 °C). (b) HCD spectrum of variant peak eluting at
27.2 min and (c) HCD spectrum of variant eluting at 26.8 min
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fragments y50, y78, and b97. To optimize the generation of
these limiting ions, filgrastim was subjected to higher energy
collision dissociation using different acceleration potentials.
By testing increasing collision potentials, fragmentation with
35 eV was selected as the best compromise between decreas-
ing b97 intensity and increasing y78 intensity (Table 1).
Online Met oxidation site assignment in H2O2-stressed
filgrastim
To simulate oxidative stress conditions, Sandoz filgrastim
drug product (Zarzio®) was treated with 0.1 and 0.5 % H2O2,
respectively, final concentration of H2O2. Oxidized filgras-
tim variants were separated by RP-HPLC and online methi-
onine oxidation site assignment was performed using our
top-down method on a benchtop Exactive MS. Oxidation
of filgrastim under these conditions produced a number of
oxidized variants that were separated by RP-HPLC (Fig. 3).
Oxidation site assignment using our top-down approach was
possible for all detected oxidized filgrastim variants. Figure 4
shows two examples of HCD spectra used for the site assign-
ment of methionine oxidation (variants labeled in red in Fig. 3a).
In Fig. 4a, the HCD spectrum of variant denoted as
Met138ox + Met127ox (0.1 % H2O2 stress) is shown. Despite
the fact that this low abundance variant represents only 0.70%
of total peak area (see Fig. 3a), all diagnostic fragment ions as
well as the intact mass of the protein were detected, albeit with
higher mass errors for the low intensity fragments. For exam-
ple, while the high-intensity fragment ion y47+16 Da
exhibited a mass error of 13 ppm, the measured mass of the
intact protein deviated by 2.1 Da from its theoretical mass.
This high mass deviation for the intact protein could be
explained by an isotope shift introduced by the deconvolution
software due to low signal intensity. In conclusion, the data
show that this filgrastim variant is doubly oxidized at residues
Met127 and Met138. Figure 4b shows the HCD spectrum of the
variant denoted as Met1ox+Met122ox+Met127ox (0.1 % H2O2,
labeled in red in Fig. 3a). Due to the low abundance of this
variant which represents only 0.12 % of total peak area, the
diagnostic ion y78+32 Da is missing. However, by consider-
ing the parent ion mass measurement, which is 48.3 Da heavi-
er than the non-oxidized filgrastim parent ion, together with
the diagnostic ions y47, y50+16 Da, and b97+16 Da allowed
us to conclude that this filgrastim variant is triply oxidized at
residuesMet1, Met122, andMet127. For two very low abundant
impurities observed in 0.1 % H2O2 stress, the native mass of
the variant denoted with [Met1ox+Met138ox+Met122ox or
Met127ox] was in agreement with triply oxidized filgrastim;
however, fragment ions representing the oxidation state at y50
and y78 were missing, thus impairing position assignment.
The abundance of the variant labeled with [4× ox] in the 0.1 %
H2O2 sample was too low to allow charge determination in the
HCD spectrum and subsequent deconvolution of the tenfold-
charged parent ion (theoretical average mass of native
filgrastim is 1,880.89 Th in the tenfold charge state).
However, a signal was detected at 1,187.30 Th, which is close
to the mass of the tenfold-charged parent ion +4× 16 Da,
suggesting the presence of filgrastim with all four methionine
residues oxidized (not shown). Unambiguous oxidation site
assignment of 4× oxidized filgrastim was possible in 0.5 %
H2O2-stressed sample where these variants were more
abundant (data not shown). While its implications remain
unclear, it is interesting to note that in the H2O2-stressed
samples, oxidation at Met122 was only observed in combina-
tion with oxidation at other methionine residues. Noteworthy,
oxidation of Met122 resulted in a major shift in RP-HPLC
retention time.
Isolated Met122 oxidation in biosimilar and originator
filgrastim stored under intended conditions
In the process of characterizing new formulations of
filgrastim being developed (Sandoz filgrastim development
sample, formulation B), two new variants were observed.
These new variants eluted much earlier in RP-HPLC
(Fig. 5a), suggesting oxidation at Met122 alone or in combi-
nation with other methionine residues. Fragment ion analysis
was able to confirm that the identity of the major unique peak
is in fact a filgrastim variant with a singly oxidized Met122
residue (Fig. 5b). In addition, we identified a very low
abundant variant as Met122 plus Met127 oxidation.
Isolated Met122 has been reported by Reubsaet et al. [12] in
H2O2-stressed samples. However, data on G-CSF oxidation
behavior published more recently as well as our data strongly
Table 1 For optimization of HCD, Sandoz filgrastim drug product
(Zarzio®) was subjected to fragmentation in the C-trap using different
acceleration potentials. Listed are intensities of selected fragment ions
relative to the highest signal in the spectrum (y47). 35 eV was selected
as the best compromise between decreasing b97 intensity and increas-
ing y78 intensity upon increase of acceleration potential
Fragment ion Mass [Da] Diagnostic for HCD 22 eV HCD 28 eV HCD 35 eV HCD 40 eV
b97 10,300.3 Met1 5 5 4 1
y78 8,488.4 Met122 (considering y50 and y47) 0 3 5 5
y50 5,332.8 Met127 (considering y47) 18 20 20 22
y47 5,073.7 Met138 100 100 100 100
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suggest that the oxidized variant denoted as oxidizedMet122 by
Reubsaet and colleagues is actually oxidized Met1.
Therefore, this is the first report of a filgrastim variant
with an isolated oxidation of Met122. Noteworthy, both var-
iants were detected in filgrastim Sandoz development sam-
ples (Fig. 5, green and blue traces) as well as in Neupogen®
(Fig. 5a, black and red traces).
Discussion
In filgrastim, oxidation of methionine residues to their sulfox-
ide derivatives is an important degradation pathway and
might become the shelf-life-limiting factor. Therefore, it is
necessary to thoroughly characterize oxidized filgrastim
variants. Oxidation of a particular methionine residue can
depend on its solvent accessibility. While Met1, Met138,
and Met127 can interact with solvent molecules, Met122 is
located at a hydrophobic region of the protein [28–30].
Oxidation of Met122 was described as relatively slow and
affected by the oxidation of Met127. The oxidation of Met122
independent from the oxidation of Met127 was confirmed in
filgrastim mutants where Met127 was substituted for a leucine
residue (M127L variant), although with very slow oxidation
rates [10].
In agreement with structural data and with earlier reports,
this study demonstrates Met1 to be most susceptible to H2O2-
induced oxidation, followed by Met138 and Met127 [10, 11,
28–31]. In H2O2-stressed samples, oxidation of Met
122
accounted for only a minor fraction of the detected impurities
(slow oxidation rate) and was always associated with the oxi-
dation of at least another methionine residue. Interestingly,
single oxidation at Met122 was observed in our filgrastim
biosimilar development samples as well as in originator batches
of Neupogen® stored at indicated conditions. As shown in
Fig. 5a, the degree of single oxidation of Met122 in these
samples was comparable to the amount of single oxidation at
Met127 or Met138 and approximately tenfold more abundant
than filgrastim with dual oxidation at both Met122 and Met127.
Although the kinetics of these oxidation events has not been
characterized in this study, the steady-state oxidation species
observed in filgrastim stored under clinically relevant condi-
tions differs strikingly from the kinetics reported for H2O2-
induced oxidation, which follows the order Met1 > Met138 >
Met127 >> Met122 [10, 11, 32]. Therefore, H2O2 stress does not
fully reflect the oxidative mechanisms which dominate during
storage. Met122 is located at the hydrophobic core of filgrastim
and its oxidation could induce a conformational change, possi-
bly explaining the strong shift observed in retention time
[28–30]. Interestingly, despite the likelihood of conformational
changes associated with Met122 oxidation, previous studies in
which Met122 was specifically oxidized using filgrastim mu-
tants demonstrated that Met122 oxidation has only a minor
effect on the biological activity [10]. However, given the
fact that the rate of Met122 oxidation depends on the formula-
tion buffer, oxidation of Met122 should be closely monitored,
especially when aiming to develop a new buffer system [14,
15].
Rapid site assignment of this new oxidized filgrastim variant
was possible with the use of a novel top-down approach using a
benchtop mass spectrometer. This Exactive instrument is a
recently introduced stand-alone Orbitrap analyzer and offers
top-down capabilities using AIF in the instrument HCD cell,
allowing high resolution and mass accuracy in both the full scan
andAIFmode in a robust and economical format [32]. AIF does
not allow the targeted selection of a specific precursor ion;
therefore, it requires reasonably pure proteins for analysis.
While this is certainly a problem in complex samples (e.g.,
periplasmic fractions), the impurities detected in the final prod-
uct are sufficiently separated by RP-HPLC beforeMS detection.
In fact, the AIF might lead to a higher sensitivity because
parent ions from all charge states are subjected to fragmen-
tation, while in “true” MS/MS approaches, only parent ions
from a single charge state are selected for dissociation, lim-
iting the detection capability. However, future experiments
will have to be carried out to determine actual differences
in method sensitivity. Based on our data, the limit of oxida-
tion site assignment from RP-HPLC-separated filgrastim var-
iants lies between 0.12 % (Fig. 4b) and 0.70 % (Fig. 4a) of
total peak area. Compared to traditional isolation/bottom-up
approaches, the high sensitivity of our top-down method
translates into significantly lower sample requirements for
characterization (10 μg per analysis for top-down compared
to 2 mg for bottom-up, assuming a variant of ∼1 % abun-
dance). Furthermore, because our method allows direct online
analysis of RP-HPLC eluents, the time required for charac-
terization was significantly shortened from about 1 week (for
isolation, digestion, and MS analysis) to 1 h.
Conclusion
The top-down approach outlined in this study describes a
highly attractive alternative to the traditional approach of
isolation/bottom-up analysis for methionine oxidation site
assignment in biopharmaceuticals. With a demonstrated sen-
sitivity as low as 0.12 % of total peak area and a throughput
of about one sample per hour, the described method is highly
suitable for a thorough characterization of oxidized me-
thionine residues in, e.g., formulation development. With
respect to instrumentation, this work shows that the
Exactive benchtop mass spectrometer operated in all-ion
fragmentation mode is a sensitive and economic tool for
online top-down characterization of less complex samples
such as microbial derived biopharmaceuticals and their
degradation products.
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